000			01811 a2200457 4500
005			20250517062719.0
264		0	_c20160614
008			201606s 0 0 eng d
022			_a2326-5205
024	7		_a10.1002/art.39492 _2doi
040			_aNLM _beng _cNLM
100	1		_aHochberg, Marc C
245	0	0	_aWhen Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program. _h[electronic resource]
260			_bArthritis & rheumatology (Hoboken, N.J.) _cFeb 2016
300			_a382-91 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAnti-Inflammatory Agents, Non-Steroidal _xtherapeutic use
650	0	4	_aAntibodies, Monoclonal, Humanized _xadverse effects
650	0	4	_aArthroplasty, Replacement _xstatistics & numerical data
650	0	4	_aChronic Pain _xdrug therapy
650	0	4	_aClinical Trials, Phase II as Topic
650	0	4	_aClinical Trials, Phase III as Topic
650	0	4	_aDisease Progression
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDrug Therapy, Combination
650	0	4	_aHumans
650	0	4	_aLow Back Pain _xdrug therapy
650	0	4	_aOsteoarthritis _xdrug therapy
650	0	4	_aOsteonecrosis _xchemically induced
650	0	4	_aProportional Hazards Models
650	0	4	_aRandomized Controlled Trials as Topic
700	1		_aTive, Leslie A
700	1		_aAbramson, Steven B
700	1		_aVignon, Eric
700	1		_aVerburg, Kenneth M
700	1		_aWest, Christine R
700	1		_aSmith, Michael D
700	1		_aHungerford, David S
773	0		_tArthritis & rheumatology (Hoboken, N.J.) _gvol. 68 _gno. 2 _gp. 382-91
856	4	0	_uhttps://doi.org/10.1002/art.39492 _zAvailable from publisher's website
999			_c25436254 _d25436254